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Glymphatic distribution of CSF-derived
apoE into brain is isoform specific and
suppressed during sleep deprivation
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Abstract
Background: Apolipoprotein E (apoE) is a major carrier of cholesterol and essential for synaptic plasticity. In brain,
it’s expressed by many cells but highly expressed by the choroid plexus and the predominant apolipoprotein in
cerebrospinal fluid (CSF). The role of apoE in the CSF is unclear. Recently, the glymphatic system was described as a
clearance system whereby CSF and ISF (interstitial fluid) is exchanged via the peri-arterial space and convective flow
of ISF clearance is mediated by aquaporin 4 (AQP4), a water channel. We reasoned that this system also serves to
distribute essential molecules in CSF into brain. The aim was to establish whether apoE in CSF, secreted by the
choroid plexus, is distributed into brain, and whether this distribution pattern was altered by sleep deprivation.
Methods: We used fluorescently labeled lipidated apoE isoforms, lenti-apoE3 delivered to the choroid plexus,
immunohistochemistry to map apoE brain distribution, immunolabeled cells and proteins in brain, Western blot
analysis and ELISA to determine apoE levels and radiolabeled molecules to quantify CSF inflow into brain and
brain clearance in mice. Data were statistically analyzed using ANOVA or Student’s t- test.
Results: We show that the glymphatic fluid transporting system contributes to the delivery of choroid plexus/
CSF-derived human apoE to neurons. CSF-delivered human apoE entered brain via the perivascular space of
penetrating arteries and flows radially around arteries, but not veins, in an isoform specific manner (apoE2 >
apoE3 > apoE4). Flow of apoE around arteries was facilitated by AQP4, a characteristic feature of the glymphatic
system. ApoE3, delivered by lentivirus to the choroid plexus and ependymal layer but not to the parenchymal
cells, was present in the CSF, penetrating arteries and neurons. The inflow of CSF, which contains apoE, into
brain and its clearance from the interstitium were severely suppressed by sleep deprivation compared to the
sleep state.
Conclusions: Thus, choroid plexus/CSF provides an additional source of apoE and the glymphatic fluid transporting
system delivers it to brain via the periarterial space. By implication, failure in this essential physiological role of the
glymphatic fluid flow and ISF clearance may also contribute to apoE isoform-specific disorders in the long term.
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Background
Apolipoprotein E (apoE), a 34 kDa protein, regulates the
transport and metabolism of cholesterol in the periphery
and central nervous system (CNS) [1–3]. In humans,
there are three major apoE isoforms that differ in one or
two amino acids; apoE2 (cysteine112, cysteine158), apoE3
(cysteine112, arginine158) and apoE4 (arginine112, ar-
ginine158). In European Americans, the prevalence of
the ε2, ε3 and ε4 alleles is 7, 78 and 15%, respectively
[4]. The most profound pathological consequence at-
tributed to apoE polymorphism is the strong associ-
ation of the ε4 allele with neurodegeneration [5].
The CNS relies primarily on de novo synthesis of apoE,
since the blood–brain barrier (BBB) restricts the transport
of apoE and cholesterol into and out of brain [6–8]. Mature
neurons have a high demand for cholesterol and while they
can synthesize it, under physiological conditions additional
supplement in the form of apoE-associated cholesterol is
used [9]. This task has been outsourced to non-neuronal
cells, the glial cells, and in particular astrocytes, considered
the main producer of brain apoE [10–16]. However, the
choroid plexus highly expresses apoE [17], and apoE is one
of the major apolipoprotein in the cerebrospinal fluid (CSF)
[3, 17–24]. The role of apoE in the CSF is unclear.
In the periphery, apoE is produced mainly by the liver
and distributed body-wide, except to the brain, via the
blood and lymphatic systems [25]. To our knowledge, it
has not been considered whether a brain-wide mechanism
for the distribution of CSF apoE exists. Recently, the
‘glymphatic system’, a fluid transporting pathway that is
functionally analogous to the peripheral lymphatic system,
was shown to be fundamental for the bulk flow/convective
flow of brain interstitial fluid (ISF) and its downstream
clearance. This system consists of CSF inflow via the peri-
vascular space of penetrating arteries, CSF/ISF exchange
and astrocytic aquaporin 4 (AQP4)-mediated bulk flow of
ISF through the parenchyma [26–30]. We reasoned that
this system is not only waste removal pathways but should
also distribute molecules in the CSF, such as choroid
plexus-derived apoE, to brain. We tested the hypothesis
that the glymphatic fluid transport also serves as delivery
and distribution pathways for choroid plexus-derived
apoE to brain. ApoE was used since its brain derived,
confined within the CNS, a known risk factor for neu-
rodegeneration and a potential therapy for Alzheimer’s
disease (AD). The aims of these studies were to estab-
lish whether apoE in the CSF and apoE secreted by the
choroid plexus into CSF were distributed into brain
via the peri-arterial space, and whether this distribu-
tion pattern was altered by sleep deprivation. The
study was necessary to determine whether apoE in
CSF can enter brain and taken up by parenchymal
cells, such as neurons, since astrocytes are believed to
be the major source of brain apoE. It is important to
the field as it provides an alternative means to target
the brain by circumventing the BBB.
Our analysis shows that the glymphatic fluid transport
plays an important role in the macroscopic delivery of
apoE, produced by the choroid plexus, to brain. CSF-
derived apoE is rapidly delivered into brain in a radial
pattern around the penetrating arterial vessels, but not
veins, in an isoform specific manner (apoE2 > apoE3 >
apoE4) and associated with neurons. ApoE parenchymal
distribution was facilitated by AQP4. In addition, sleep
deprivation suppresses glymphatic CSF-derived apoE
distribution into brain and its clearance. Thus, speculat-
ing, failure of the glymphatic fluid transport may con-
tribute to apoE related disorders, in the long-term.
Methods
Mice
Male C57BL/6 J and NG2-DsRed (Tg(Cspg4-Ds Red.-
T1)1Akik/J) mice, which are on C57BL/6 J genetic
background, were purchased from Jackson Laboratory
(Bar Harbor, ME). In mice older than 6–8 weeks,
oligodendrocyte progenitor cells rarely express Ds-
Red, which is restricted to peri-vascular smooth
muscle cells and pericytes [26, 31]. In these mice,
arteries and arterioles are labeled with DsRed, whereas
veins are DsRed negative [26]. The AQP4 ko (Aqp4−/−)
mice were obtained from Dr Nagelhus and generated
as described [32]. While there was no significant sex
differences in glymphatic fluid transport of apoE in
young mice, males were used for consistency. The
mice were housed in the vivarium facilities at the University
of Rochester, School of Medicine and Dentistry. All animal
studies were performed according to the NIH guidelines
using protocols approved by the University of Rochester
Committee on Animal Resources. Mice were housed at a
maximum of five per cage, as permitted, depending on the
experiment, and maintained on a 12:12 light/dark schedule
(6 AM: 6 PM) with food and water ad libitum. Mice were
anesthetized with a mixture of ketamine (100 mg/kg) and
xylazine (10 mg/kg) by intraperitoneal injection (IP).
Materials
The lentivirus (pTANK-CMVie-LckEGFP-WPRE) ex-
pressing membrane-bound enhanced green fluorescent
protein (EGFP) was designed to carry, in the 5' to 3'
direction, a central polypurine tract (cPPT) element, a
cytomegalovirus (CMV) immediate early promoter,
membrane-bounded EGFP, expressed in tandem with a
Woodchuck Hepatitis Virus Posttranscriptional Regu-
latory Element (WPRE). Virus particles (called lenti-
EGFP) pseudo typed with vesicular stomatitis virus G
glycoprotein were produced, concentrated by ultracen-
trifugation, and titrated on 293HEK cells (1.0 x1012
colony forming unit/ml) [33, 34]. Lentivirus-apoE3
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(OHS 5899–202616165; Precision LentiORF.APOE3
with stop codon) was obtained from GE Dharmacon,
Inc. (Lafayette, CO, USA). The apoE3 was cloned into
LentiORD plasmid under the control of the CMV pro-
moter. The expression cassette contains CMV, apoE3, IRES,
EGFP and WPRE. We referred to this apoE3 gene delivery
as lenti-apoE3 to compare with the lenti-EGFP particle.
The internal ribosome entry site (IRES) provides for bicis-
tronic expression, but the expression of EGFP is low com-
pared to that of apoE3 in this cassette. Thus, to get a good
signal of EGFP expression that is similar to that of apoE3
we used a mixture of both lenti-EGFP and lenti-apoE3 to
provide a more rigorous test of the transduced cells (EGFP)
in the presence of released apoE3 (detected by immunola-
beling of the human apoE) in some experiments where
stated. Reconstituted human lipidated-apoE2, −apoE3 and
-apoE4 were obtained from Dr. David Holtzman. The
particle size (10–17 nm) and disc shape were similar to the
range of HDL-like particles derived from astrocytes or
isolated from human CSF [12, 14, 15, 35, 36], and also simi-
lar to the reconstituted apoE [35]. The size and shape of
lipoproteins in CSF are heterogeneous and may be species
dependent [3, 37]. We used human apoE, the most abun-
dant apolipoprotein in CSF, and our analysis only detects
apoE. The apoE particles were purified by gel filtration-
FPLC (Fast Protein Liquid Chromatography) to minimize
the loss of proteins and antibody affinity column, and the
particle size determined by non-denaturing gel electro-
phoresis followed Western blot analysis [12, 35]. In
addition, the particle size of each of the three apoE isoform
was similar [35]. ISF clearance of apoE is not affected by its
particle size [6]. The particle size is within the size of the
gaps (~20 nm) between astrocytic end feet [38, 39]. FITC-
tagged apoE was prepared following the manufacturer’s
instructions (FITC Protein labeling Kit (F-6434, Life Tech-
nologies, Carlsbad, CA, USA). ApoE labeled with Alexa
Fluor 647 was prepared following the manufacturer’s
instructions (Alexa Fluor 647, Microscale Protein Labeling
Kit (A30009), Molecular Probes, Inc., Eugene, OR, USA).
Lectin was obtained from Vector Laboratory (Lycopersicon
esculentum (tomato); Burlingame CA, USA).
Transduction
Lentivirus carrying only EGFP or human apoE3 was stereo-
tactically injected into the right lateral ventricle (co-ordi-
nates: anteroposterior, −0.4 mm; mediolateral, +1.0 mm
and dorsoventral, −2.3 mm), using a pulled glass pipette
connected to a Hamilton syringe that is driven by a micro-
injector pump controller (Micro 4, World Precision Instru-
ments, Inc., Sarasota, FL), at 1 μL/min for 3 min. At the
end of the injection, the pipette was left at the injection site
for 10 min to prevent reflux of the injectate along the injec-
tion track. It was removed slowly over 2 min. After 1 to
8 weeks post-transduction mice were re-anesthetized and
perfusion fixed with 4% paraformaldehyde (PFA). Brains
were sectioned horizontal at 100 μm thickness using a
vibratome (Vibratome Series 1000). Sections were observed
for EGFP expression, and processed for immunolabeling of
various proteins, including human apoE.
Immunohistochemistry
Immunohistochemistry was performed as reported
[40, 41]. Mice were transcardially perfused with ice-
cold phosphate buffered saline (PBS, pH 7.4, Sigma-
Aldrich, St. Louis,MO,USA) followed by 4% PFA
(Sigma-Aldrich). Free floating brain sections (100 μm;
horizontal or coronal) were immunolabeled for various spe-
cific markers, such as neurons (NeuN) and astrocytes
(GFAP). The tissue was blocked with 7% donkey serum for
1 h and incubated with the primary antibodies overnight.
The primary antibodies were rabbit anti-human specific
anti-apoE (1:200, Abcam Inc., Cambridge, MA; ab52607),
mouse anti-aquaporin 1 (1:200, Abcam. Ab9566), mouse
anti-GFAP (1:500, Sigma, G3893), chicken anti-NeuN
(1:500, Abcam, ab134014), chicken anti-GFP antibody
(Novus Biological,Littleton, CO,USA. NB100-1614). Then,
Alexa Fluor-conjugated secondary antibodies were added
and incubated for 2 h at room temperature (Life Technolo-
gies, 1:500). DAPI (Sigma, 1:2000) was used to identify cell
nuclei. Immunofluorescence was visualized using a Bio-Rad
MRC500 confocal scanning head attached to an inverted
microscope (IX81, Olympus, Tokyo, Japan) controlled by
Olympus Fluoview 500 software. For analysis of apoE inten-
sities immunohistochemistry was performed on 100 μm
vibratome-cut brain slices. Neurons were identified by
NeuN labeling, astrocytes by GFAP expression and blood
vessels by lectin staining. Arteries were identified by the red
NG2-DsRed expression. NIH ImageJ software (1.47v) was
used to measure the intensity of apoE immunoreactivity.
Background intensities (5 per image) were measured in the
parenchyma of the same field and subtracted from apoE
intensities. The intensity of the immunolabeled apoE on
the vessel wall and around (a 5 μm band around the vessel)
arterial vessels or veins were quantified in the brain regions
of three mice. For co-localization of apoE and neurons, a
total of 30 neurons were quantified per brain and the aver-
age determined. The person analyzing the images and data
was blinded to the experimental design.
Intracisternal injections
Mice were anesthetized, fixed to a stereotactic frame and
the cisterna magna exposed and cannulated using a 30G
needle [26, 42]. Fluorescent tracers (5 μL aCSF containing
apoE (0.5%) and cascade blue tagged dextran (10 kDa, 1%)
as the reference inert molecule that is not significantly
taken up by cells, transported across the BBB or degraded)
were injected at 1 μl/min using a Hamilton syringe
connected to a Micro Syringe pump controller (Micro 4;
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World Precision Instruments, Inc.). The same amount of
apoE was used for each isoform for comparison. We used
a small volume and a slow rate of injection (5 μL at 1 μL/
min), that does not significantly increase the intracranial
pressure [28], thereby minimizing CSF reflux into the
cerebral ventricles from the cisterna magna [26]. ApoE4
and dextran (10 kDa) were used to characterize the tech-
nique since, in contrast to the dextran, apoE4 is retained
within the brain to a greater extent compared to the other
isoforms [6]. These tracers should provide a better reso-
lution of CSF flow around arterial vessels. To quantify the
glymphatic fluid inflow into brain, 125I-apoE, at a low con-
centration (10 nM, due to the greater resolution of radio-
activity analysis), and 14C-inulin (6 kDa, 1.0 μCi, an inert
molecule) were intracisternally injected at 1 μL/min for
5 min and after 30 min the brain removed and prepared
for radioactivity analysis (see below).
Lectin administration
Lectin was administered during the cardio-perfusion stage
of the experiment, i.e., intravascularly. The mice were
cardio-perfused with cold PBS, containing lectin (0.02 mg/
ml), at 2 ml/min for 10 min. This was then followed by
perfusion with PFA (4% in PBS), as described above.
In vivo 2-Photon imaging
In anesthetized mice, a craniotomy (3 mm in diameter)
was made over the sensory motor cortex. The dura was
left intact and the craniotomy was covered with aCSF
and sealed with a glass coverslip. To visualize the vascu-
lature, 0.1 ml BBB impermeable Texas Red-dextran 70
(MW 70kD; 1% in saline, Invitrogen) was injected intra-
venously immediately before imaging. A Mai Tai laser
(SpectraPhysics) attached to a confocal scanning system
(Fluoview 300, Olympus) and an upright microscope
(IX51W, Olympus) was used for in vivo imaging as
described [26, 27]. A 20X (0.9NA) water immersion lens
was used to image the cortex, from the surface to a
depth of ~150 μm at every 5 μm z-steps. We used
870 nm as excitation wavelength and emission was
collected at 575-645 nm. The cerebral vasculature was
imaged at a resolution of 512 × 512px. FITC-apoE3 was
administered intracisternally at 1 μL/min for 5 min and
images acquired at 15 min after the injection.
Sleep deprivation
Mice were sleep deprived from 6 to 9 AM and used im-
mediately for the experiment at zeitgeber time 3 (ZT3).
Sleep deprivation was maintained by using an enriched
environment, containing novel objects and nesting mater-
ial, to facilitate spontaneous exploration by the mice, as
reported [43]. Mice were continuously observed to ensure
that they were indeed awake and exploring the objects.
Mice that were not exploring the objects were lightly
prodded or gently handled to encourage their continuous
activity. This method was chosen to minimize stress to
the mice [43]. Food and water were freely available.
Brain clearance
Earlier, it was shown that iodination (125I-) of lipidated
apoE did not affect its clearance from brain ISF when
compared to untagged lipidated apoE [44]. There are
differenced in clearance rate between lipid-poor and lipi-
dated apoE [6, 44]. Thus, if there were changes in the
apoE lipidated state with iodination then it should have
altered its clearance rate. To evaluate solute clearance
from the brain, radio-labeled tracers (125I-apoE3 (prepared
as we reported [6]) and 14C-inulin (6 kDa, PerkinElmer)
were injected stereotaxtically into the left frontal cortex,
as we recently reported [27]. Briefly, a stainless steel guide
cannula (Plastic One) was implanted stereotaxically into
the left frontal cortex of anesthetized mice (2% isoflurane)
with the coordinates of the cannula tip at 0.7 mm anterior
and 3.0 mm lateral to the bregma, and 1.0 mm below the
surface of the brain. Animals were allowed to recover after
surgery and the experiments performed 18–24 h after the
guide tube cannulation, as reported [45]. Experiments
during sleep state and sleep deprivation were performed
between ZT3 and ZT4. In each mouse, a small volume of
mock CSF (0.5 μL), containing 125I-apoE (10 nM) and
14C-inulin (1.0 μCi), was simultaneously injected (33 GA
cannula, Plastic One) into the brain ISF over 5 min. At
the end of the experiments (90 min) the brain was
removed and prepared for radioactivity analysis. Samples
were first counted for gamma radioactivity (125I-apoE)
using Wallac 1471 Wizard Automatic Gamma Counter)
and counts corrected for TCA-precipitability, as reported
[45]. Then all samples were solubilized in 0.5 ml tissue
solvable (Perkin Elmer) overnight followed by the addition
of 5 ml of scintillation cocktail (Packard Ultima Gold).
Samples were then analyzed in a liquid scintillation counter
for 14C- radioactivity (LS6500 Multi-purpose Scintillation
Counter (Beckman Coulter, GA, USA). Calculations: The
percentage of radioactivity remaining in the brain after
microinjection was determined as % recovery in brain =
100 x (Nb/Ni) (eq. 1), where, Nb is the radioactivity
remaining in the brain at the end of the experiment and Ni
is the radioactivity injected into the brain ISF. Total
clearance was determined as 100-%recovery. 14C-inulin
was used as an inert polar molecule which is neither
transported across the BBB nor significantly retained by
brain cells; its clearance provides a measure of the ISF
bulk flow/convective flow. To confirm that FITC labeling
apoE do not affect apoE clearance, we microinjected
FITC-apoE3 or 125I-apoE3 intracortically, as above, and
after 90 min the apoE3 levels remaining in brain were
determined and expressed as a percentage of the injected
dose that was cleared from brain, as reported [26, 46].
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Levels of FITC-apoE3 were determined fluorometrically,
as reported [47] and 125I-apoE3 analyzed as we reported
[6].
Flow (Diffusion) radius
A custom ImageJ plugin program was written to analyze
apoE distribution radius as a function of distance from
the vessel wall. In these studies, horizontal brain sections
(100 μm each) from the cortex were used as there were
no regional differences in apoE uptake from CSF. Arteries
were identified by red NG2-DsRed (smooth muscles)
expression in the NG2 DsRed reporter mice, veins were
NG2 DsRed negative and the vasculature was labeled with
lectin. The vessel diameter was calculated from the brain
photomicrographs containing lectin immunofluorescence.
The digital images of photomicrographs were used for the
image analysis using imageJ software. The plugin plotted
the intensity value of the immunofluorescence with
respect to distance when a line was drawn across the
blood vessel identified by the lectin immunofluorescence.
Based on the change in the intensity value the blood vessel
diameter was calculated. The cortical brain region was
used since penetrating arteries were analyzed and there
were no regional differences. All arterial vessels were
analyzed in each brain section by a person blinded
to the experimental design. Three horizontal brain
sections (sensory-motor cortex) were used per mouse
brain and there were 5 to 9 mice per group.
Cell culture
Primary cultures of mouse astrocytes and choroid plexus
epithelial cells were performed, as reported [40, 48]. In
brief, the choroid plexus from the lateral ventricles and 4th
ventricle were removed from 15 C57BL6 male mice (4–8
weeks old), digested in 0.4% pronase in Hank’s balanced
salt solution (HBSS) and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing fetal bovine serum
(FBS), epidermal growth factor (EGF) and antibiotics
(penicillin/streptomycin) on collagen coated wells. The
purity of the choroid plexus epithelial cells was typically
>99%, as determined from AQP1 immunolabeling and
insignificant levels of astrocytes (GFAP-positive cells), and
neurons (NeuN-positive cells). For cultured astrocytes,
neocortical astrocytes were prepared from P1 to P4
C57BL/6 mouse pups, as previously described [40]. Briefly,
cerebral cortices were separated and meninges were
removed. The cortical tissue was dissected and washed
three times in HBSS without Ca2+. After trituration and
filtering through the 70-μm nylon mesh, the cells were
centrifuged at 200 g for 10 min. The pellet was dissociated
to single cell suspension in DMEM/F12, containing 1%
Penicillin/Streptomycin and 10% FBS, and plated in T25
culture flasks. Typically, cultures with more than 99% of
GFAP-positive cells were used in this study. All cells were
grown at 37 °C in a humidified incubator (5% CO2/98%
humidity). Medium was changed after 24 h and every
3 days thereafter. Conditioned media from the near con-
fluent cells were collected, complete protease inhibitors
(Roche Applied Sciences) added, centrifuged at 2000 g for
10 min to remove cellular debris and stored until required
for analysis. Cells were then washed with PBS, harvested,
pelleted and sonicated in lysis buffer.
Brain extraction
Frozen cerebral cortex was sonicated in eight times
volume of ice-cold RIPA lysis buffer, containing
complete protease inhibitor (Roche Applied Sciences)
and 30 mM β-mercaptoethanol (BME), and centri-
fuged at 10,000 g for 15 min in a microcentrifuge at
4 °C (Eppendorf ). The supernatant was used to deter-
mine apoE levels using Western blot analysis. The
same amount of total protein was loaded into each
well. Protein levels were determined by using a BCA
protein assay kit (ThermoFisher, Scientific).
Western blot analysis
ApoE3 levels were determined by western blot analysis.
Ice-cold CSF (10 μL) and standards (apoE3, 0.1 mg/ml)
were diluted in an equal volume of Laemmli sample buffer
(BioRad Laboratories, Hercules, CA; 161-0737) supple-
mented with 200 mM dithiothreitol (DTT; Sigma). Equal
volumes (20 μL) of CSF and apoE3 standards were added
to the sample wells of 4–15% Precast Gels (Mini-Protein
TGX, BioRad, 456-0783) for electrophoresis under reducing
conditions followed by transfer to a nitrocellulose mem-
brane (BioRad, 162-0115) and detection using human
specific anti-apoE antibody (Abcam, Ab52607; 1;1000) and
a secondary antibody (goat anti-rabbit IgG-HRP, Santa
Cruz sc2030; 1:10,000). For mouse apoE levels in brain a
mouse specific anti-apoE with extremely low recognition of
human apoE [49] was used (1:500; Ab20874, Abcam).
Mouse apoE in the conditioned media was detected with
an antibody (Calbiochem; Cat # 178479). Blots were devel-
oped using enhanced chemiluminescence (SuperSignal,
34077, Pierce, Rockford, IL). Levels of apoE3 in CSF were
determined from the linear part of the standard curve that
was generated from the intensities of Western blots of
known amounts of apoE3. The relative abundance of
human and mouse apoE in brain were determined with
reference to β-actin. Conditioned media from the primary
cultures of choroid epithelial cells and astrocytes were
concentrated by ultrafiltration using a 10 kDa cut-off filter
(Amicon Ultra Centrifuge Filters, 10 k NMWL, Merck
Millipore, Cork, Ireland). The wells were loaded with equal
volume of the concentrated conditioned media, and un-
saturated intensities standardized to the protein concentra-
tion of the cultured cells.
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ApoE ELISA
Human apoE3 levels were determined using a human apoE
specific ELISA kit (Abcam, Ab 108813) by following the
manufacturer’s instructions. Samples of CSF from controls
(Lenti-EGFP) were used to confirm human specificity. This
signal was subtracted from the signal obtained in the CSF
collected from the lenti-apoE3 transduced mice. Levels of
apoE3 were determined from a standard curve.
Statistical analysis
Data were analyzed using either Student’s t test when
comparing two groups or analysis of variance (ANOVA)
followed by post hoc Tukey test when comparing more
than two groups. The differences were considered to be
significant at p < 0.05. All values were expressed as
mean ± SEM.
Results
While apoE is expressed in many types of brain cells [17],
astrocytic endfeet surrounding the large blood vessels
displays high levels of apoE immunolabeling [50, 51], but
it is unclear whether these vessels are arteries or veins. To
assess whether apoE levels differ in the astrocytes
surrounding arteries and veins, we used NG2-DsRed
reporter mice in which arterial vessels (vascular smooth
muscle cells) and pericytes, but not veins, are labeled with
DsRed [26, 31]. Higher endogenous apoE immunolabeling
around large arteries and arterioles than that around large
veins in several regions (cortex, hippocampus and stri-
atum) was consistently observed (Fig. 1a-i). While there
were no regional differences, quantitative immunohisto-
chemical analysis of apoE showed that the intensity on the
vessel wall and around arterial vessels was about 2.3-3.0-
fold and 2.1-2.5-fold greater compared to that on the walls
and around veins, respectively (Fig. 1j). Since this distribu-
tion pattern may reflect a greater density of astrocyte on
the arterial vessel walls compared to that of veins, astro-
cytes were immunolabeled with glial fibrillary acidic
protein (GFAP), an astrocytic marker. The number of





































Fig. 1 Greater levels of arterial endogenous mouse apoE than that on veins. Representative images of arteries and veins in brain regions (a, d and g at
low magnification. Scale bar (100 μm). b cortical arteries with NG2-DsRed positive smooth muscle cells immunostained for apoE (blue) and (c) cortical
vein lacking smooth muscle cells and with little apoE. Scale bar (50 μm). Similar pattern of apoE immunolabeling on arteries (e and h) and veins (f and
i) in the hippocampus (d-f) and striatum (g-i). Blue, apoE; red, NG2-dsRed; green, Lectin. j Quantification of the apoE intensities on the vessel wall and
around (a 5 μm circle around the vessel) arteries and veins in the different brain regions (cortex (Cx), hippocampus (HP) and striatum (ST)). Arterial wall
(red column), peri-arterial (orange), vein (blue), peri-venous (green). White box (arterial vessels). Yellow box (venous vessels) Values are mean ± SEM. N = 4
mice per group
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were labeled with endogenous apoE was greater than that
on veins (Additional file 1: Figure S1A-G), as reported
[52], which confirms the data shown in Fig. 1. Thus, this
distinct distribution pattern may reflect higher levels of
astrocytic-derived apoE around arterial vessels, or alterna-
tively, that CSF apoE enters along the peri-arterial space
and is taken up primarily by astrocytes surrounding larger
arteries and arterioles. If so, this spatial distribution of en-
dogenous apoE suggests the existence of a polarized (ar-
teries to veins) transport system that facilitates its
distribution within the ISF.
We then explored whether apoE in CSF enters brain
via the perivascular space. First, we intracisternally ad-
ministered Alexa-647 labeled human-lipidated apoE4
(apoE4-647) and a reference molecule, cascade blue-
labeled dextran (CB; 10 kDa, fixable) (Fig. 2a), to estab-
lish the appropriate time point for further studies. At
various post-injection times, mice were perfusion-fixed
with 4% paraformaldehyde (PFA) followed by horizontal
(rather than coronal) brain section. These procedures
allowed us to evaluate apoE distribution as a function of
distance from the vessel wall. To clearly visualize the en-
tire vasculature, lectin, a vascular marker, was adminis-
tered intravascularly. Radial distribution pattern of both
molecules (CB > apoE4-647) was seen around arterial
vessels but not veins (Additional file 2: Figure S2A-B).
The radial distribution increased progressively with
post-injected time with CB distributing, due to the bulk
flow of ISF, further from the vessel wall than that of
apoE4-647 (Fig. 2b-e). Surprisingly, the distribution of
apoE4-647 was limited and quickly approached equili-
bration. Interestingly, the distribution of non-lipidated
apoE4-647 was greater than that of lipidated apoE4-647
(Additional file 3: Figure S3A-H), which may explain the
higher ISF clearance of non-lipidated apoE isoforms
compared to their lipidated counterparts [6]. The dis-
tance of apoE distribution from the vessels wall was then
standardized to that of the reference molecule (Fig. 2f ).
We selected 15 min after the intracisternal injection to
study the CSF inflow into brain since it appears that
equilibration occurs at about 25 min and to allow for
changes, either increase or decrease.
To confirm the highway by which CSF-derived apoE
enters into brain, we used two-photon laser scanning
microscope to visualize the pathway along vessels through
a closed cranial window in anesthetized mice. The cerebro-
vasculature was clearly visualized by intravascular injection
of the BBB impermeable Texas red-dextran (70 kDa). Intra-
cisternal injected apoE3-647 entered the perivasculature
space along surface arteries and penetrating arterioles
(Fig. 3a-h), as reported for other molecules [26, 27]. Inflow












































Fig. 2 Distribution of CSF apoE4 around arteries but not veins (a) Schematic diagram showing the intracisternal injection site. b-d Representative
images of apoE4-647 (red) and dextran-cascade blue (CB) radial distribution at 10, 25 and 50 min post-intracisternal injection. Scale bar = 100 μm.
e Distribution distance of apoE4 and CB at different post-injection times. f ApoE4 distribution distance standardized as a percentage of that of CB.
Values are mean ± SEM. N = 4. The vasculature was outlined by intravascular labeling with lectin (green)
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injection was seen within the periarterial space at various
depths below the brain surface (Fig. 3b-h). We then used ex
vivo brain sections to confirm these results and apoE’s
presence in other parts of the vasculature, such as
capillaries and veins. ApoE3-647 and CB (10 kDa) were
intracisternally injected and lectin was administered
intravascularly to label vessels in NG2-DsRed reporter
mice. We confirm the presence of apoE3-647 and CB
in the perivascular space of arterial vessels and their
distribution into the parenchyma (Fig. 4a-h). To confirm
the clearance routes, apoE3-647 and CD was injected
(0.5 μL at 0.1 μL/min) into the parenchyma (caudate puta-
men) and after 60 min the brain sections analyzed for the
location of these molecules along vessels. ApoE3-647 and
CB was present along capillaries (Fig. 4i-k) and deep cere-
bral parenchymal veins (Fig. 4l-m). Clearance of apoE was
confirmed by using 125I-apoE3 (10 nM) and 125I-apoE4
(10 nM), as shown (Additional file 3: Figure S3I). Iodin-
ation (125I-apoE) does not affect clearance when compared
to unlabeled apoE [44]. Furthermore, FITC labeling of
apoE3 does not affect it clearance when compared to 125I-
apoE3 (Additional file 3: Figure S3J).
Next, the distribution of the three apoE isoforms was
compared to establish whether there are isoform-specific
effects. Unexpectedly, the radial distribution from the
arterial wall was apoE isoform specific, with apoE2 and
apoE3 having greater radial flow than that of apoE4 even
though the particle size of each isoform was similar and
the same amount of apoE was injected (Fig. 5a-d). The
distribution radius of apoE2 was 1.75-fold greater than
apoE3, which in turn was 2-fold greater than apoE4. These
observations are consistent with the hypothesis that apoE
binds avidly to apoE receptors and that the brain retention
of apoE4 is greater that apoE3 and apoE2 [6, 53–55], and
thus, bulk flow of apoE4 is much more restricted com-
pared to apoE2. The distribution distance of CB was not
affected by the apoE isoforms (Additional file 4: Figure
S4). To determine whether apoE4 degradation contributed
to its restricted distribution, radiolabeled apoE (10 nM)
was intracisternally injected and after 30 min the brain
was removed and TCA-precipitable radioactivity assessed.
The level of TCA-precipitable 125I-apoE (intact apoE) in
the brain was similar for each isoform (Additional file 5:
Figure S5). Thus, there was no significant difference in
apoE degradation between the isoforms, as reported for
up to 300 min [6, 44]. To establish whether CSF apoE is
an important source of neuronal apoE, we intracisternally
injected FITC-apoE3, and after 15 min, perfused and PFA
fixed the brain. Brain sections were then immunolabeled
with NeuN, a neuronal specific nuclear biomarker that is
used extensively. The CSF injected FITC-apoE3 was asso-
ciated with peri-arterial neurons (NeuN-positive cells;
Fig. 5e). Interestingly, apoE was associated with the
nucleus, as reported [56, 57]. Intracisternal injected FITC-
ovalbumin (45 kDa) or FITC-dextran (40 kDa, fixable)
was not present in the nucleus of neurons (Additional file
6: Figure S6 A-H). However, intracisternal injected un-
labeled apoE3, detected with a specific anti-human apoE
antibody, was present in the nucleus (Additional file 6:
Figure S6 I-L). Thus, CSF apoE enters the brain paren-
chyma via the periarterial space, taken up by neuronal
cells and some of the apoE enters the nucleus.
z=0μm z=25μm z=50μm z=75μm z=100μm
z=125μm z=150μm
FITC-apoE3/TR-Dextran
A B C D E
F G H
Fig. 3 ApoE periarterial inflow using in vivo 2-photon imaging (a) Pial surface arterial vessels showing apoE3-FITC within the perivascular space of
arteries. b-g ApoE3-FITC along the perivascular space of penetrating arterial vessel at various depths below the brain surface. h Magnified image
of the white boxed area in (panel b) (scale bar 50 μm). Following intracisternal injection (5 μL at 1 μL/min) of apoE3-FITC images were acquired
every 25 μm below the brain surface at 15 min. The scale bar in (panel g) is 50 μm. Panels a-g are at the same magnification. The vasculature
was identified by intravenously injected Texas Red-dextran (70 kDa)
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Since AQP4 mediates ISF distribution we used Aqp4−/−
mice, as reported in similar studies [26]. The radial distri-
bution of apoE3 was considerably reduced in the Aqp4−/−
mice compared to littermate controls (Fig. 6a-c). Similarly,
cascade blue labeled dextran (10 kDa) distribution was
reduced (Additional file 7: Figure S7A-B). In addition, in
Aqp4−/− mice, the brain uptake of 125I-apoE2, 125I-apoE3
and 125I-apoE4 (10 nM), after their intracisternal injection,
was equally suppressed (Additional file 7: Figure S7C).
Similarly, 14C-inulin brain uptake was reduced and not
affected by apoE isoforms (Additional file 7: Figure S7D).
A previously report has shown that other CSF tracers,
such as Aβ and ovalbumin, were reduced by 60% in Aqp4
−/− mice [26]. Thus, CSF apoE is distributed into brain
parenchyma by glymphatic fluid transport in a radial
pattern around arterial vessels.
ApoE, produced by the choroid plexus and secreted into
the CSF, could be an important source of ISF apoE, since
CSF is circulated through the brain parenchyma by glym-
phatic fluid transport [26, 27, 29, 30]. To test whether
apoE produce by the choroid plexus is delivered to the
brain parenchyma, we transduced the choroid plexus with
a lentivirus encoding a human apoE construct (lenti-
apoE3) and mapped apoE3 distribution with a human
specific apoE antibody. First, we injected lenti-EGFP into
the lateral ventricle and found that it intensely transduced
the choroid plexus and ependymal cells but not parenchy-
mal cells (Additional file 8: Figure S8A-E). We confirmed
that endogenous apoE is highly expressed in the choroid
plexus (Additional file 9: Figure S9). We next found that
lenti-apoE3 delivered intraventricularly intensely trans-
duced the choroid plexus and ependymal layer, as seen for
lenti-EGFP (Fig. 7a-d; Additional file 8: Figure S8A-E). In
addition, apoE3 neuronal uptake increased with post-
transduction time (Fig. 7e-l). To confirm that the lenti-
virus did not transduce neurons and astrocytes, we



























































Fig. 4 ApoE is cleared from brain along perivascular pathways a Low magnification image showing the distribution of intracisternally injected apoE3-647
and cascade blue (10 kDa) in brain 15 min after their injection (5 μL at 1 μL/min). b-d Magnified images of the boxed area in (panel a). e Magnified images
of the boxed area in (panel d). f-h Cross section of a cortical penetrating artery showing the perivascular flow of apoE3-647 and cascade blue. i Intensity
graph of the various fluorescent markers across the white line drawn in (panel h). j-l Presence of apoE3-647 and cascade blue in a representative cortical
capillary 60 min after intraparenchymal injection (caudate nucleus, 0.5 μL at 0.1 μL/min). m-n Presence of apoE3-647 and cascade blue in a representative
deep cerebral parenchymal vein 60 min after intraparenchymal injection (caudate nucleus). Intracisternal apoE3-647 (magenta) and cascade
blue (blue) entered brain via the penetrating cortical arterial vessels (red) and distributed within the parenchyma. Panels a-h are images after
intracisternal injection of apoE3-647 and cascade blue in NG2-DsRed reporter mice. Lectin-FITC was injected intravascularly to identify vessels.
Panels j-n are images after intraparenchymal (caudate nucleus) injection of apoE3-647 and cascade blue in NG2-DsRed reporter mice. Scale
bars: A = 100 μm, B-D = 50 μm, E-H and J-N =10 μm. PVS = perivascular space
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injected a mixture of lenti-EGFP and lenti-apoE3 into the
lateral ventricle and after 4 weeks analyzed brain sections.
In these experiments a mixture of both lenti-EGFP and
lenti-apoE3 was used since the IRES bicistronic expression
of EGFP is low compared to that of apoE3 in this expres-
sion cassette. Thus, to get a good EGFP signal we used a
mixture of both lenti-EGFP (to identify the transduced
cells only) and lenti-apoE3 (to identify the expressed
apoE3 by immunolabeling) to achieve a more rigorous test
of the transduced cells. In Additional file 10: Figure S10,
EGFP expression (lenti-EGFP) shows the transduced cells,
































Fig. 5 ApoE-isoform specific distribution around arteries. a-c Representative images of apoE2, apoE3 and apoE4 (colored red) radial distribution
15 min following their intracisternal injections. Scale bar 100 μm for the left panels and 50 μm for the middle/right panels. d Quantification of the
distribution distance from the arteries. Values are mean ± SEM. N = 5–9. e FITC-apoE3 in the CSF binding to NeuN- positive neurons (red) in the
vicinity of arteries. White arrows point to apoE3/NeuN- double positive cells (the image is 100 μm wide). The vasculature was outlined by intravascular





















Fig. 6 CSF apoE distribution in brain is reduced in Aqp4 −/− mice. Representative images of FITC-apoE3 radial distribution from the arteries
in littermate controls (a) and Aqp4−/− (b) mice. c Quantification of the distribution distance from the arteries. Values are mean ± SEM, N = 5
mice per group
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contrast, human apoE3 secreted by the transduced cells
(lenti-apoE3) was detected by immunolabeling, and shown
to be present in these regions and in the brain paren-
chyma (Additional file 10: Figure S10 A-H). Thus, the
lentivirus was taken up only by local cells, the choroid
plexus and ependymal cells, as shown for viral transduc-
tion [49, 58].
In addition, human apoE3, determined by Western
blot analysis and by ELISA with a human specific anti-
apoE antibody, was present in CSF collected from the
lenti-apoE3 transduced mice (Fig. 8a-c). Furthermore,
primary culture of mouse choroid plexus epithelial cells
secreted similar levels of apoE compared to primary
culture of mouse astrocytes (Additional file 11: Figure
S11A-B). The purity of the cultured choroid plexus epi-
thelial cells and astrocytes were typically >99% (Additional
file 11: Figure S11C-F). Mouse brain apoE levels were un-
changed in the lenti-apoE3 transduced mice compared to
that of the lenti-EGFP transduced mice (Fig. 8d-e). While
an accurate determination of human apoE levels cannot
be compared to mouse apoE since different antibodies
were used, the estimated brain apoE3 levels in the trans-
duced mice represent about 25% of the endogenous
mouse apoE (Fig. 8d-e). Taken together these data show
that apoE3, secreted by the choroid plexus into CSF, was
delivered to the brain via glymphatic fluid transport [26].
We have shown that glymphatic inflow of CSF into brain
was reduced in mice that were awake compared to the
sleep state [27]. Thus, we reasoned that lack of sleep would
reduce CSF inflow into brain and thereby, decrease the
delivery of CSF-derived apoE to brain. Mice were sleep





























Fig. 7 ApoE3 levels in brain cells increase following lenti-apoE3 transduction of the choroid plexus. a Lenti-apoE3 effectively transduced the choroid plexus
and ependymal layer at 1 week post-transduction. ApoE3 immunolabeled with a human specific anti-apoE antibody. b-d Choroid plexus expression of
apoE3 at 8 weeks post-transduction. Scale bar 100 μm. AQP1 (red; b); apoE3 (green; c) and merged images (d). e-j Parenchymal human apoE3 (green) at 1
(e-f), 4(g-h) and 8 (i-j) weeks post-transduction. Scale bar 100 μm. Neurons: NeuN-positive cells (blue). Astrocytes: GFAP -positive cells (red). k Human specific
anti-apoE does not react with endogenous mouse apoE. l Quantification of apoE3 intensities in neurons (apoE co-localization with NeuN-positive cells) with
post-transduction time. Lenti-apoE3 delivered intraventricularly (3 μL lenti- apoE (4.06 × 108 TU/ml) and after 1 to 8 weeks the brains were perfusion fixed
(PFA) followed by immunolabeling of brain sections. Representative images from 5 mice per group. Values are mean ± SEM. N= 5
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brain determined at zeigeber time 3 (ZT3; Fig. 9a). The
analysis showed that sleep deprivation significantly reduced
the radial distribution of apoE3 around arterial vessels com-
pared to mice on normal sleep cycle (Fig. 9b-f). Similarly,
the radial distribution of cascade blue labeled-dextran was
reduced in sleep deprivation (Additional file 1: Figure
S12A-B). In addition, inflow of CSF-derived 125I-apoE2,
125I-apoE3 and 125I-apoE4 (10 nM) and 14C-inulin into
brain was reduced to the same degree during sleep
deprivation (Additional file 12: Figure S12C-D).
Interestingly, clearance of 125I-apoE3 (10 nM) and
14C-inulin from the ISF was also reduced in the sleep
deprived mice compared to those in the sleep state
(Fig. 9g-i).
Discussion
The analysis presented here shows, for the first time, that
choroid plexus/CSF-derived apoE is delivered into brain,
via glymphatic fluid transport, in an apoE-isoform specific
(apoE2 > apoE3 > apoE4) radial distribution pattern around
penetrating arterial vessels, but not veins. Aqp4−/− mice
exhibited a significant decrease in the apoE distribution in
brain due to the reduced ISF bulk flow and apoE-isoform
distribution cannot be resolved, i.e., loss of the isoform spe-
cific distribution. Perhaps most interestingly, sleep
deprivation was associated with a striking reduction in CSF
delivered apoE to the parenchyma, and a loss of apoE-
isoform specific distribution into brain also due to the re-
duced ISF bulk flow. These observations of radial apoE dis-
tribution from arterial vessels of CSF-derived apoE support
the novel concept of a macroscopic distribution mechanism
of compounds secreted by the choroid plexus into brain.
Speculating, failure of glymphatic CSF inflow into brain, as
in sleep deprivation, may, in the long-term, contribute to
apoE related disorders and eventually neurodegenerative
diseases [59–62].
It’s well established that the choroid plexus is a major
source of CSF [63–65]. However, the choroid plexus also
secretes essential substances into CSF, such as transthyretin,
which binds thyroxine to facilitate its distribution within
CSF and brain [66, 67]. In addition, blood-derived mole-
cules, such as apoA1, enter brain via the choroid plexus
[68]. Glymphatic fluid transport may be the medium for
the delivery of these molecules from CSF to brain. There
are a number of findings that collectively strongly indicates
that the choroid plexus also regulates the levels of apoE. In
Abca1−/− mice, brain apoE levels were reduced [11, 69], but
CSF levels were almost completely suppressed [11]. Liver X
receptors (LXR) are sensors of cellular cholesterol that










































































































Fig. 8 Increased CSF and brain apoE3 levels in lenti-apoE3 transduced choroid plexus. a Representative Western blots of apoE3 standards (top) and
apoE3 in CSF and plasma from lenti-EGFP (controls) and lenti-apoE3 transduced mice. Quantification of CSF apoE3 levels by Western blot analysis at
4 weeks post-transduction (b), and by ELISA at 4 (left) and 8 (right) weeks post-transduction (c). d Levels of brain endogenous apoE and human apoE3
in the transduced mice. e Quantification of mouse apoE levels by Western blot analysis. Values are mean ± SEM. N = 4-5. Intraventricular (unilateral)
injection of 3 μL lenti-human apoE (4.06 × 108 TU/ml) or 3 μL lenti-EGFP (1012 TU/ml). At 4 and 8 weeks post-transduction samples of CSF, plasma and
brain were collected
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transporter A1 (ABCA1) and other genes involve in lipid
metabolism. Activating LXR in the CNS increases CSF
levels of apoE and cholesterol more profoundly compared
to brain levels. LXR activation increases apoE expression in
the choroid plexus [21], and ABCA1 levels and cholesterol
release from the choroid plexus [20]. Despite these observa-
tions the significance of this source of apoE to brain paren-
chyma apoE levels has been ignored. Since the glymphatic
system allows CSF to enter brain by bulk flow, apoE in the
CSF may contribute to parenchymal apoE. While neurons
can synthesize cholesterol they may need additional choles-
terol delivered in the form of apoE-associated cholesterol
[9]. In the Niemann-Pick type C1 mouse, which has a mu-
tant NPC1 gene, cholesterol accumulates in the late
endosome and lysosomes in neurons, suggesting uptake of
apoE-associated cholesterol via clathrin-coated pit pathway
[70, 71]. Interestingly, the expression of apoE in astrocytes,
the main producer of brain apoE, is not uniform in brain
[17].
ApoE, a cargo transporter and a cell signal molecule,
has essential and diverse role in the CNS [7]. It’s involved
in neuritic growth, synaptic plasticity, regeneration and
remyelination of axon and cognition [72]. As a cargo






















































Fig. 9 Sleep deprivation reduces the apoE3 arterial radial diffusion and clearance. a Schematic representation of the experimental design. Representative
images at low (left) and high (right) magnification of the cortex (b) and hippocampus (c) in mice on normal sleep cycle. Representative images at low (left)
and high (right) magnification of the cortex (d) and hippocampus (e) in sleep deprived mice. f of the distribution distance from the arteries in the cortex of
control (sleep (S); clear column) and sleep deprived (SD; red column) mice. Fluorescently-tagged apoE3 was injected into cisterna magna of NG2dsRed
reporter mice and perfusion fixed (PFA) at 15 min. The vasculature was outline by lectin (gray). ApoE, green; NG2-dsRed, red. Scale bars 100 μm (A-D, left),
50 μm (A-D, right). g Schematic diagram showing the intracortical injection site. h-i 125I-ApoE3 and 14C-inulin clearance from the frontal cortex in the sleep
and sleep deprived states. Values are mean ± SEM. N= 5 mice per group
Achariyar et al. Molecular Neurodegeneration  (2016) 11:74 Page 13 of 20
and essential for the delivery of cholesterol and lipids to
cells [25]. Our data demonstrated that CSF may serve as a
medium for the delivery of apoE to brain via glymphatic
fluid transport, as reported for other solutes, such as Aβ
[26, 30], lipophilic molecules [29] and tau [73]. Within
brain, ISF is distribute by bulk flow, which has been estab-
lished using inert molecules that is not significantly taken
up by receptor mediated transport into cells, degraded or
transported across the BBB [74–86]. We have confirmed
bulk flow of ISF since inert molecules of different mol-
ecule weights (mannitol 180 Da vs dextran 10,000 Da and
inulin 6,000 Da vs dextran 40,000 Da) are cleared at the
same rate, i.e., bulk flow [26, 46]. Earlier reports suggested
that molecules transported along the peri-vascular space
occurs in the opposite direction to cerebral blood flow,
i.e., brain to CSF [50, 51, 87, 88]. Flow of ISF from brain
to CSF may occurs along the vascular basement [86].
While it is possible for bidirectional trafficking along the
vessel [86], more investigation will be needed to clarify
this fully.
What is the importance of CSF-derived apoE to brain
apoE since astrocytes produce apoE? Primary astrocytes in
culture secrete apoE [14], and this could be taken up into
local neurons by receptor-mediated endocytosis [89]. Our
data show that CSF-derived apoE is taken up by neurons,
in vivo. Thus, astrocyte-derived apoE is not completely
blocking CSF-derived apoE from accessing these cells. In
other words, astrocytic apoE is not saturating all apoE
receptors on the cell surface that would prevent the up-
take of CSF-derived apoE. Thus, CSF-derived apoE may
be an important source of brain apoE. The glymphatic
fluid transport of CSF-derived apoE may also prevent dilu-
tion and wash out of astrocyte-secreted apoE, and facili-
tate a wider distribution of apoE within the parenchyma.
In addition, glymphatic re-circulation of apoE may con-
tribute to its slow turnover rate [90], and retention within
brain [6].
ApoE polymorphism influences its structure and func-
tion [4]. Compared to apoE2 and apoE3, the arginine resi-
due at position 112 of apoE4 may promote interactions
between the N-terminal (receptor-binding region) and C-
terminal (lipid-binding region) domains, which causes
instability [4, 24]. Thus, the apoE isoform specific radial
distribution of CSF-derived apoE around arteries could re-
flect its cellular uptake, which restricts the flow of apoE
within the ISF, especially apoE4. Cells along the glympha-
tic pathways express many types of apoE receptors, such
as low-density lipoprotein receptor (LDLR) and LDLR-
related protein 1 (LRP1). These receptors are expressed in
many cell types, including vascular smooth muscles,
neurons, glia and endothelial cell [91–93]. Lipidated apoE,
the normal form of apoE and the apoE used in the present
studies, avidly binds to apoE receptors [6, 53, 94, 95].
There are subtle differences in the binding constants of
each apoE isoform to apoE receptors [94]. For example,
apoE2 binds LDLR 50- to 100-times weaker than apoE3
and apoE4 and this may explains it greater distribution
radius [96]. Interestingly, apoE isoform specific retention
within brain (apoE4 > apoE3 > apoE2) [6] corroborate the
data obtained for their radial distribution from the arterial
wall (apoE4 < apoE3 < apoE2).
Glymphatic activity is regulated by the sleep/wake state:
with inflow of CSF into brain greater during the sleep state
compared to wakefulness [27]. Sleep is also required for
greater bulk flow of brain ISF and clearance of solutes [27],
consolidation of memory and plasticity [60]. Many studies
have focused on the effect of sleep deprivation on synaptic
plasticity at the molecular and electrophysiological levels,
and on the structural aspects of brain regions associated
with learning and memory, such as the hippocampus [97].
To our knowledge there are no studies on the effect of
sleep deprivation on brain-wide delivery of CSF-derived
apoE. While many factors may contribute to the mechan-
ism for the observed changes during sleep eprivation [98],
increased noradrenaline levels [99, 100] may play a role in
reducing glymphatic fluid transport, as reported [27]. The
causes of sleep deprivation are complex and multifactorial,
which involves many biological factors, including metabolic
and neurotransmitter changes [101, 102]. We use a milder
procedure to induce sleep deprivation to minimize major
changes. CSF inflow into brain via the periarterial space
and ISF clearance are reduced during wakefulness com-
pared to the sleep state, and antagonist of norepinephrine
induced a sleep-like response in CSF inflow [27]. It is pos-
sible that norepinephrine released during ‘sleep deprivation
stress,’ even though this was minimized, may contribute to
the reduced CSF inflow and ISF clearance. Interstitial levels
of norepinephrine are increased in the unstrained mice
compared to mice in the sleep-like state [27]. Sleep
deprivation may increase the sympathetic tone [103], espe-
cially in mice that are sleep deprived for the first time and
when they want to sleep (light switched off). Norepineph-
rine may cause vasoconstriction of pial arteries [104], and
this may contribute to the reduced CSF inflow during sleep
deprivation. Recently, it was show that Aβ40 in CSF caused
a reduction in CSF inflow via the periarterial space, possible
due to vasoconstriction of pial arteries [30]. Thus, impaired
CSF inflow during sleep deprivation may be due to vaso-
constriction of the pial vessels, and this may also contribute
to the reduced glymphatic fluid transport. Speculating,
failure in the delivery of CSF-derived apoE to brain during
sleep deprivation may limit the brain-wide distribution of
apoE and other essential substances to brain cells, which
may, in the long-term, contribute to apoE related dysfunc-
tion [105–108]. Further work is needed to explore other
possible mechanisms.
The implications of these findings are that reduced
glymphatic inflow into brain, as seen in sleep deprivation,
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the wake state [27], aging [42] and in brain injury and
trauma [46, 73], could reduce the delivery and distribution
of apoE to brain, which may lead to apoE related disorder
in the long-term. However, a dilemma is that the apoE
isoform specific restriction to arteries may lead to the de-
velopment of cerebral amyloid angiopathy (CAA), vascular
dementia and AD. The apoE4 isoform predisposes
heightened susceptibility to AD and CAA [109, 110].
Intriguingly, the reduced glymphatic perivascular flow
with aging and brain injury may facilitate the develop-
ment of CAA due to the slower transit time that will
cause greater cellular binding/update of apoE, espe-
cially apoE4. While apoE2 has the longest distribution
it was reported to be associated with greater incidence
of micro hemorrhage as was apoE4 [111–113].
Gene therapy targeting the choroid plexus to enhance
the production of apoE2 or to produce apoE2 in apoE4
allele carriers may extend the apoE distribution radius
[114]. Viral transduction was effective in selectively trans-
ducing the choroid plexus and ependymal cells [49, 58].
The use of lentivirus to target the choroid plexus, via intra-
ventricular injection, could minimize tissue injury due to
intra-cerebral injections [115]. Further work is needed in a
model of AD to evaluate the effect of this intervention on
glymphatic fluid transport and in preventing cognitive de-
cline. Despite decades of research it is still unclear whether
therapies to lower or increase brain cholesterol is require to
treat AD [49, 116, 117]. Altering CSF apoE levels may pro-
vide better insights into the level and form of apoE require
for its sustained beneficial effects. Fig. 10 shows a schematic
diagram of our working model.
Conclusion
The analysis shows, for the first time to our knowledge,
the following:
1) Choroid plexus/CSF-derived apoE is rapidly
delivered into brain, via glymphatic fluid transport,
in an apoE isoform specific (apoE2 > apoE3 > apoE4)
radial distribution pattern around arterial vessels,
but not veins.
2) Aqp4−/− mice exhibited a significant decrease in the
apoE distribution in brain.
3) ApoE3, delivered to the choroid plexus by lentivirus,
was present in the CSF and delivered to brain cells






















Fig. 10 Schematic diagram of our working model for apoE delivery and distribution by the glymphatic system. This schematic diagram shows
the parenchymal distribution of CSF-derived apoE isoform-specific convective flow/bulk flow pattern (apoE2 > apoE3 > apoE4) around an artery.
CSF-derived apoE is present on the vessel wall and around the artery. The apoE distribution is shown as a circle around the artery for simplicity
but its bulk flow (unequal distribution around the artery). Within the brain there are many cells, such as neurons, astrocytes that express many
membrane bound receptors that avidly binds apoE. Symbols: A - penetrating arteriole; V - vein; - apoE; - AQP4; There are many different types
of apoE receptors, such as - apoE receptor mainly on astrocyte and - apoE receptor mainly on neuron
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4) Sleep deprivation was associated with a reduction in
CSF inflow into brain and clearance from the
parenchyma.
5) These observations of radial apoE distribution from
arterial vessels of CSF-derived apoE support the novel
concept of a macroscopic distribution mechanism of
compounds secreted by the choroid plexus into brain
via the CSF inflow along the periarterial space.
6) Speculating, failure of this glymphatic CSF inflow
into brain, as in sleep deprivation, may, in the
long-term, contributes to apoE related dysfunction.
Additional files
Additional file 1: Figure S1. More GFAP-positive astrocytes on the arterial
wall than that on veins. a-e) Representative images of GFAP-positive astrocytes
on the wall and around arteries and veins. The vasculature was outline by
lectin (green) in NG2dsRed reporter mice and perfusion fixed (PFA) at 15 min.
A) Astrocytes (GFAP, blue), B) Vessels (lectin-FITC, green), C) arteries (NG2-
dsRed, red), D) endogenous apoE (purple) and E) Merged images. Images of
GFAP-positive astrocytes around an artery (identified by the expression of
NG2-DsRed and vasculature staining with lectin) as shown in the yellow box
in C (F) and a vein (identified by the lack of NG2-DsRed expression but with
the vasculature stained with lectin) as shown in the white box in C (G). Scale
bars: 100 μm (A-E), 50 μm (F-G). Arrow heads (panel F) identify some astrocytic
endogenous apoE. (EPS 7646 kb)
Additional file 2: Figure S2. ApoE4 radial distribution around arteries
is shorter than that of dextran. A) Representative images of radial
distribution around arteries but not veins for dextran-cascade blue
(inert reference molecule, CB) and apoE4-Alexa647 (apoE-647, purple)
after 10 min post-injection in NG2Ds-Red (NG2, red) reporter mice.
The vasculature was outlined by intravascular labeling with lectin
(green). Scale bar = 100 μm. Arteries (yellow arrow head). Veins (blue
arrows). B) A custom made image J plugin was used to generate the
mean radial distribution of cascade blue labeled dextran (Dextran-CB,
blue) and apoE4-Alexa647 (colored red) from the lectin stained vessel
wall (green). Distribution from the vessel wall was determined at
1000 intensity units and maximum intensity indicate saturation at
4096 intensity units (212 – 12 bit image depth). (EPS 32092 kb)
Additional file 3: Figure S3. Radial distribution around arteries is greater
for non-lipidated than lapidated apoE4. A-H) Representative images (from 3 to
4 mice) of radial diffusion of non-lipidated (A-D) and lipidated apoE4-Alexa647
that was colored green (E-H) at 10 min after their intracisternal injection in
NG2ds-Red (NG2, red) reporter mice. The vasculature was outlined by
intravascular labeling with lectin (colored blue). Scale bar = 100 μm. I)
Clearance of 125I-apoE3 and 125I-apoE4 (10 nM) 90 min after their
intracortical injection (0.5 μL over 5 min). J) FITC-apoE3 (10 nM) or 125I-apoE3
(10 nM) ISF clearance were similar 90 min after their intracortical injection.
Values are mean ± SEM, n = 5-6 mice. (EPS 26205 kb)
Additional file 4: Figure S4. ApoE isoforms does not affect cascade
blue-dextran radial distribution. Similar radial distribution distances of
dextran-cascade blue (CB) in the presence of apoE2 (E2), apoE3 (E3) and
apoE4 (E4) at 15 min after their intracisternal injection. Values are mean ±
SEM, N = 5-9. (EPS 564 kb)
Additional file 5: Figure S5. No differences in apoE degradation in
brain. Brain levels of TCA-precipitable 125I-apoE isoforms (intact) 30 min
after their intracisternal injection. Values are mean ± SEM, N = 5. (EPS 567 kb)
Additional file 6: Figure S6. ApoE in the nucleus of neurons but not
FITC-dextran or FITC-ovalbumin. A-C) FITC-ovalbumin (45 kDa, green) is
not present in the nuclei of NeuN-positive neurons (red). D) Magnified
image (boxed area in panel C) showing the NeuN-positive nucleus lacking
FITC-ovalbumin labeling. E-G) FITC-dextran (40 kDa, green) is not present in
the nuclei of NeuN-positive neurons (red). H) Magnified image (boxed area in
panel G) showing the NeuN-positive nucleus lacking FITC-dextran labeling.
Scale bar: 100 μm (A-C and E-G), 50 μm (D and H). I-K) Unlabeled apoE3 (10
nM) injected intracisternally was taken up by NeuN-positive nucleus
at 30 min. L) Magnified image of the boxed area in panel K. Scale bars
25 = μm. (EPS 48178 kb)
Additional file 7: Figure S7. Reduced cascade blue radial distribution
and apoE inflow into brain in Aqp4 −/− mice. Representative images of
cascade blue dextran (10 kDa, blue) radial distribution in littermate
controls (A) and Aqp4−/− (B) mice. Cascade blue dextran was injected
intracisternally, and the mice perfusion-fixed at 15 min. The vasculature
was outline by lectin (green). Scale bar is 100 μm. C) Inflow of CSF-derived
125I-apoE2 (yellow column,10 nM), 125I-apoE3 (red column, 10 nM) and 125I-
apoE4 (orange column, 10 nM) into brain was suppressed in Aqp4−/− mice.
D) Inflow of CSF-derived 14C-inulin into brain was suppressed in Aqp4−/−
mice. Values are mean ± SEM. N = 6 mice per group. (EPS 14922 kb)
Additional file 8: Figure S8. Lenti-EGFP effectively transduced the
choroid plexus. A) Lenti-EGFP unilateral injected into the lateral ventricle
preferentially transduced the choroid plexus and ependymal layer but
not brain parenchyma at 1 week. DAPI (blue); EGFP (green). B-E) Lenti-EGFP
expression in the choroid plexus at 1 week. Images are DAPI (blue; B), AQP1
(red; C); EGFP (green; D) and merged images (E). Scale bar 50 μm.
Intraventricular injection of 3 μL lenti-EGFP (1012 TU/ml). N = 5.
(EPS 75360 kb)
Additional file 9: Figure S9. Endogenous apoE expression in the
choroid plexus. Immunolabeling of mouse endogenous apoE in the
choroid plexus. Note the high apoE expression level in choroid plexus.
Blue, DAPI; green, apoE; red, NG2-dsRed; gray, Lectin. (EPS 824 kb)
Additional file 10: Figure S10. Lenti-apoE3 transduced the choroid
plexus but not the parenchyma cells. A-H) Representative images showing
transduction in the choroidal cells of lenti-apoE3 and lenti-EGFP at 4 weeks
after intraventricular delivery. A) Merged image showing choroid plexus (CP;
scale bar, 100 μm). B) EGFP (green); C) apoE3 (magenta); D) AQP1 (red); E)
merged images of B, C and D (scale bar 50 μm). Arrows show apoE3 in
choroidal cells in C and E. F-H) cortex (Cx) showing no transduction (no
EGFP) (F, scale bar 200 μm) but the presence of apoE3 (G-H). H, scale bar
50 μm. Lenti-apoE3/lenti-EGFP mixture was delivered intraventicularly (3 μL
lenti-human apoE (4.06 × 108 TU/ml) and lenti-EGFP (1012 TU/ml) and after
4 weeks the brains were perfusion fixed followed by immunolabeling.
(EPS 41288 kb)
Additional file 11: Figure S11. Cultured primary mouse choroid plexus
epithelial cells secrete apoE. A) Representative apoE images from Western
blots of the conditional medium from choroidal epithelial cells and
astrocytes. B) Primary cultured choroidal epithelial cells (CP) produced
similar levels of apoE as astrocytes (astro). Values are mean ± SEM, N = 4.
C) Representative image of AQP1, a marker of choroid plexus epithelial
cell, expression in the cultured primary mouse choroid plexus. Lack of
significant immunolabeling of NeuN (neurons; D) and GFAP (astrocytes; E)
in the cultured CP epithelial cells. F) Expression of GFAP in the cultured
primary mouse astrocytes. DAPI (blue). (EPS 15343 kb)
Additional file 12: Figure S12. Sleep deprivation reduces the dextran
radial distribution and 125I-apoE inflow from CSF into brain. A-B) Representative
images of cascade blue dextran (CB) in mice on normal sleep cycle (A) and in
mice during sleep deprivation (SD) (B). Cascade blue dextran (10 kDa) was
injected into cisterna magna and the mice perfusion fixed (PFA) at 15 min.
The vasculature was outline by lectin (green). Scale bars 100 μm (A-B). C) 125I-
ApoE2 (yellow column), 125I-apoE3 (red column) and 125I-apoE4 (orange
column) inflow into brain from the CSF were reduced in SD mice. D) 14C-inulin
inflow into brain from the CSF was reduced with SD and not affected by apoE
isoforms. 125I-ApoE (10 nM) and 14C-inulin were intracisternally injected and
the brain analyzed for radioactivity. Values are mean ± SEM. N= 6 mice per
group. (EPS 15099 kb)
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